Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Genitourinary 1Endocrine 1

Conditions

Thyroid Neoplasms 5Thyroid Carcinoma, Anaplastic 4Neuroendocrine Tumors 4Thyroid Cancer, Papillary 3Carcinoma, Medullary 3Adenocarcinoma, Follicular 2Wilms Tumor 1Vipoma 1Thyroid cancer, medullary 1Thyroid cancer, Hurthle cell 1Thyroid Diseases 1Somatostatinoma 1Neoplastic Cells, Circulating 1Multiple Endocrine Neoplasia Type 2b 1Multiple Endocrine Neoplasia Type 2a 1Insulinoma 1Glucagonoma 1Gastrinoma 1Familial medullary thyroid carcinoma 1Differentiated Thyroid Cancer 1Carcinoma, Islet Cell 1Carcinoma, Hepatocellular 1Carcinoid Tumor 1Adrenocortical Carcinoma 1Adenoma, Islet Cell 1

Interventions

tipifarnib 1entrectinib 1entinostat 1cixutumumab 1cabozantinib 1Sorafenib 1Ritonavir 1Radiotherapy 1Indinavir 1Cytoreduction Surgical Procedures 1Cyclophosphamide 1Cisplatin 1Biological Factors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Wilms Tumor × Sorafenib × Endocrine × Clear all
NCT01502410 2018-06-26

Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer

National Cancer Institute (NCI)

Phase 2 Completed
20 enrolled 14 charts
EndocrineGenitourinaryHead & Neck

Thyroid Cancer, Papillary, Wilms Tumor, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡